News

Dr. Califf Is Confirmed as FDA Commissioner; NORD Issues Statement


 

References

Following the confirmation by the U.S. Senate of Robert Califf, MD, as Commissioner of the Food and Drug Administration (FDA), NORD President and CEO Peter L. Saltonstall issued the following statement:

“On behalf of the rare disease community, I want to congratulate Dr. Califf on being confirmed as Commissioner of the FDA. Dr. Califf has spoken to NORD in the past and is familiar with the special issues facing our community. We look forward to working with him closely in the future.”

Prior to joining FDA in February 2015, Dr. Califf was Professor of Medicine and Vice Chancellor for clinical and translational research at Duke University. He is an internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research.

Recommended Reading

NIH Launches Online Application Portal for Undiagnosed Diseases Network
MDedge Dermatology
Patient Organizations May Apply to Join Natural History Study Project
MDedge Dermatology
Rare Disease Community Prepares for Worldwide Observance of Rare Disease Day
MDedge Dermatology
Omnibus Spending Bill Includes Provisions Important to the Rare Disease Community
MDedge Dermatology
FDA Invites Patient Organizations to Organize Public Meetings to Enhance Awareness of Their Needs
MDedge Dermatology
NIH Releases Its Strategic Plan
MDedge Dermatology
EADV: DLX105 is a novel treatment strategy for Behçet’s flares
MDedge Dermatology
A Case of Bloom Syndrome With Uncommon Clinical Manifestations Confirmed on Genetic Testing
MDedge Dermatology
Elevated cardiovascular risks linked to hidradenitis suppurativa
MDedge Dermatology
EHR Report: How Zika virus reveals the fault in our EHRs
MDedge Dermatology